Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $405 from $390 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines’ Combo Cancer Trial Reaches Completion: What Investors Should Watch Next
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS
- Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial
- Jazz reports efficacy, safety results from Phase 3 HERIZON-GEA-01 trial
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint